Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConduit Hldg Regulatory News (CRE)

Share Price Information for Conduit Hldg (CRE)

Share Price is delayed by 15 minutes
Get Live Data
445.00    8.50 (1.95%)
Bid:
444.50
Ask:
445.00
Spread: 0.50 (0.112%)
Market Cap: £658.17m
CRE Live PriceLast checked at - London Stock Exchange

Intraday Conduit Hldg Share Chart

Interim Management Statement

18 Feb 2008 07:00

Creston PLC18 February 2008 18 February 2008 Creston plc Interim Management Statement Creston plc (LSE: CRE), the Insight and Communications Group, announces itsinterim management statement for the period 1 October 2007 to 31 December 2007. Operational Trading The Group continued its consistent track record of achieving growth in excess ofthe industry average. Trading during the first three quarters of FY08 is aheadof the prior year, with revenue growth across the Group of 20 per cent and on alike-for-like basis 8 per cent. This continued growth has been achieved despite the present volatile economicenvironment and given the structural shift from off-line to on-line which istaking place within the industry. During the year the Group increased its investment in its existing operations tomaintain its market leading client proposition. This investment was twofold: (i) in new sector specialisations, such as International Healthcare PR and Corporate Communications; and (ii) in resource and freelance for the fast growing area of digital and online. This strategy has proven successful, as demonstrated by the addition of a numberof new blue chip client wins in the third quarter such as Capital One, FirstDirect, Homeform, Royal Mail, Thorpe Park, Toshiba Computers and others to itsalready diverse and impressive client base. Inevitably, the investments have caused a lower profit conversion on incrementalrevenue and a small decline in the Headline operating profit margin year on yearfrom over 18% to 17% for the April to December period. This operating margin isafter accounting for head office costs and Creston US and remains one of thebest in the industry. Against the current uncertain economic environment, it is even more important tomaximise the operating profit margin and actions included to date are: a) the formation of a Digital Forum with the brief to reduce the resource cost and improve the efficient delivery of projects; b) further centralisation of the Insight division's data capture and back offices; and c) the formation of a Healthcare Board to maximise client synergy opportunities and develop a truly integrated approach to clients' marketing needs. Operating cash flow during the period remained good and is in line withmanagement's expectations of a 100% conversion from operating profit. The group maintains significant headroom in each of its banking covenants and atthe period end had over £16 million of unutilised banking facility available.This unused facility plus annual operating cash flow are to be used to settleearn out commitments due over the next three financial years. The earn outliability is contingent upon the companies in earn out achieving growth up tothe end of the 2009 financial year. USA Creston announced in its Interim statement for the period ended September 2007that it had decided to put acquisitions in the USA on hold, due to the thenconcern over a potential downturn in the American economy. The global economic uncertainty and volatility has only increased since theInterim statement and more so in the USA than in most other countries.Consequently, the Board has decided to close its NY office and absorb the dutiesof building the Creston offering to American clients from within its London headoffice. As a consequence, Steve Blamer will be stepping down as CEO of CrestonInc. The costs incurred to date and of closing the office are approximately£600,000 in total and will be fully disclosed in the preliminary results. Outlook As demonstrated by the above market revenue growth to date, the Group continuesto perform well in a period of economic uncertainty and when there is growingevidence of clients delaying spend in the market research sector. As newbusiness was strong across both divisions in the quarter and the pipelineremains very positive, the Board expects to be in line with broker revenueforecasts. The Board remain confident of delivering absolute and like-for-like growth inoperating profit compared to the prior year. The Group's continued significantinvestment in digital and online resource is expected to result in a lowerprofit conversion on the revenue growth and therefore a small reduction in thefull year operating profit margin. The Board believes that Creston, with its diversified and growing online model,is well placed to weather any future economic uncertainty and it will be pleasedto report in mid-June on its progress in the preliminary results for the fullyear ending 31 March. For further information, please contact: Creston plc 020 7930 9757 Don Elgie, Chief Executive Barrie Brien, COO/CFO www.creston.com------------------ Hogarth Partnership Limited 020 7357 9477 Chris Matthews/Sarah Macleod About Creston plc • Creston is an Insight and Communications marketing services group. TheBoard's aim is to identify synergistic benefits between its marketing servicescompanies offering premium services such as market research, direct andinteractive marketing, advertising, public relations, insight and to build aGroup that offers clients solutions to both existing and future marketing needsacross both on-line and off-line channels. • Creston's companies boast a range of blue-chip clientsincluding the AA, AstraZeneca, BA, Bayer, BMW, BT, Burger King, Capital One,Canon, COI Communications, Cow & Gate, Diageo, eBay, First Direct, GeneralMotors, George Wimpey, GlaxoSmithKline, Halifax, Homeform, Kimberly-Clark,Lexus, Lloyds Black Horse, Morrisons, Nestle Rowntree, Nissan, Norwich Union,Pfizer, Roche Diagnostics, Royal Mail, Sainsbury's, Tesco, Thorpe Park, Toshiba,T-Mobile, Tropicana, Unilever, Vodafone, Walkers and WH Smith. • Creston's share price is quoted in the Financial Times, TheDaily Telegraph, The Times and the London Evening Standard. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Dec 20233:45 pmRNSPurchase of Shares by Employee Benefit Trust
7th Dec 20232:22 pmRNSPurchase of Shares by Employee Benefit Trust
6th Dec 20232:52 pmRNSPurchase of Shares by Employee Benefit Trust
6th Dec 20237:00 amRNSPurchase of Shares by Employee Benefit Trust
5th Dec 20233:46 pmRNSPurchase of Shares by Employee Benefit Trust
1st Dec 20235:28 pmRNSPurchase of Shares by Employee Benefit Trust
30th Nov 20233:28 pmRNSPurchase of Shares by Employee Benefit Trust
29th Nov 20233:51 pmRNSPurchase of Shares by Employee Benefit Trust
29th Nov 20237:00 amRNSHolding(s) in Company
28th Nov 20234:41 pmRNSPurchase of Shares by Employee Benefit Trust
27th Nov 20233:17 pmRNSPurchase of Shares by Employee Benefit Trust
24th Nov 20232:02 pmRNSPurchase of Shares by Employee Benefit Trust
23rd Nov 20234:25 pmRNSPurchase of Shares by Employee Benefit Trust
22nd Nov 20235:06 pmRNSPurchase of Shares by Employee Benefit Trust
17th Nov 20234:20 pmRNSPurchase of Shares by Employee Benefit Trust
8th Nov 20237:00 amRNSDirectorate Change
8th Nov 20237:00 amRNSThird Quarter 2023 Trading Update
26th Oct 20237:00 amRNSNotice of Q3 2023 Trading Update and Webcast
25th Sep 20237:00 amRNSDirector/PDMR Shareholding
18th Aug 20237:00 amRNSDirector/PDMR Shareholding
18th Aug 20237:00 amRNSDirector/PDMR Shareholding
15th Aug 20237:00 amRNSDirector/PDMR Shareholding
15th Aug 20237:00 amRNSDirector/PDMR Shareholding
1st Aug 20233:59 pmRNSDirector/PDMR Shareholding
28th Jul 20237:00 amRNSDirector/PDMR Shareholding
27th Jul 20235:20 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSConduit Interim Results 2023
25th Jul 20237:00 amRNSDirectorate Change
14th Jul 20232:55 pmRNSNotice of H1 2023 Results and Conference Call
22nd Jun 20237:00 amRNSNotice of IFRS 17 Briefing Call
15th Jun 20234:48 pmRNSHolding(s) in Company
13th Jun 20237:00 amRNSDirector/PDMR Shareholding
23rd May 20237:00 amRNSTransfer of Treasury Shares
19th May 20234:56 pmRNSDirector/PDMR Shareholding
19th May 20237:00 amRNSDirector/PDMR Shareholding
18th May 20237:00 amRNSResults of 2023 AGM
17th May 20237:00 amRNSFirst Quarter 2023 Trading Update
4th May 20234:20 pmRNSNotice of Q1 2023 Trading Update and Webcast
17th Apr 20232:09 pmRNSNotice of AGM
6th Apr 20232:50 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
22nd Mar 20237:00 amRNSHolding(s) in Company
7th Mar 20234:28 pmRNSDirector/PDMR Shareholding
6th Mar 202311:25 amRNSPublication of 2022 Annual Report and Accounts
22nd Feb 20237:00 amRNSYear ended 31 December 2022 Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.